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Abstract: Video-assisted thoracoscopic surgery (VATS) has been
known to be a stressful event for patients, and dexmedetomidine is
known to attenuate surgery-induced sympathetic responses and potenti-
ate analgesia in perioperative periods. The present was designed to
evaluate the effects of intraoperative dexmedetomidine administration
on the quality of recovery (QoR) and pulmonary function after VATS.
Patients with lung cancer undergoing VATS were randomized to
Dex group (loading of 1.0mg/kg for 20minutes before the termination
of surgery, n¼ 50) or Control group (comparable volume of normal
saline, n¼ 50). The QoR-40 questionnaire assesses postoperative recov-
ery and validates the overall surgical and general anesthesia outcomes.
The QoR-40 scores, forced expiratory volume for 1 second (FEV1) on
postoperative day (POD) 1 and 2, and emergence agitation were
evaluated.The global QoR-40 score (162.3 17.8 vs 153.3 18.7,
P¼ 0.016 on POD 1; 174.3 16.0 vs 166.8 16.7, P¼ 0.028 on
POD 2) and FEV1 (2.1 0.4 vs 1.9 0.5 L, P¼ 0.034 on POD 1;
2.2 0.5 vs 2.0 0.4 L, P¼ 0.030 on POD 2) were significantly higher
in the Dex group compared with the Control group on POD1 and POD 2.
The score of emergence agitation was lower in the Dex group compared
with the Control group (3 [2–5] vs 5 [3–7], P< 0.001). The number of
patients indicating severe emergence agitation was shorter in the Dex
group than Control group (0 [0%] vs 7 [14%], P¼ 0.048). The length of
hospital stay was significantly shorter (6.7 [3–9] vs 8.4 [4–9] days,
P¼ 0.045) in the Dex group compared with the Control group.
Intraoperative dexmedetomidine administration improved QoR,
postoperative pulmonary function, and emergence agitation in patients, Jin Gu Lee, MD Kim, MD,
ng Jun Oh, MD, PhD
(Medicine 95(7):e2854)
Abbreviations: BIS = bispectral index, Dex = dexmedetomidine,
FEV1 = forced expiratory volume in 1 second, NRS = numeric
rating scale, PaCO2 = partial pressure of arterial carbon dioxide,
PACU = post-anesthetic care unit, PaO2 = partial pressure of
arterial oxygen, PCA = patient-controlled analgesia, POD =
postoperative day, QoR = quality of recovery, VATS = video-
assisted thoracoscopic surgery.
INTRODUCTION
V ideo-assisted thoracoscopic surgery (VATS) has a widerange of applicability, including the diagnosis and treat-
ment of lung cancer, and has gradually replaced conventional
thoracotomy. VATS is minimally invasive compared with open
thoracotomy, with known benefits including lesser postopera-
tive pain and the possibility of earlier mobilization.1,2 However,
patients undergoing VATS also complain of a moderate degree
of acute postoperative pain.2,3 Furthermore, the incidence of
chronic postoperative pain has been reported to be similar to
that with open thoracotomy.4–6 Present study indicate that
approximately 40% patients undergoing surgery for lung cancer
experience psychological distress and mood changes, which
somewhat higher than the incidence associated with cancers of
other organs.7 Therefore, patients who undergo VATS should
not be underestimated and neglected in regards to appropriate
treatment for acute postoperative pain and psychological stress
to avoid adverse effects on the postoperative quality of life
and morbidity.
Dexmedetomidine is a selective a2-agonist and a sedative
with anti-inflammatory,8,9 analgesic,10,11 and antiemetic
effects,12 and its use for procedural sedation during endoscopy13
or ablation for atrial fibrillation has been increasing.14 It is also
used for sedation in the intensive care unit. Recently, it was
reported that dexmedetomidine is often used as an adjuvant for
general anesthesia.15 Sympatholysis of dexmedetomidine can
attenuate the increased sympathetic tone after surgery and result
in antistress effects. In addition, opioid-sparing and analgesic
effects are promoted by the perioperative administration of
dexmedetomidine.10,16,17
The Quality of Recovery questionnaire (QoR-40) is a tool
used to assess the quality of recovery after surgery through
questions pertaining to 40 items related to 5 domains. It has been
validated as a global and reliable measurement tool18,19 and isot only for surgeons but also anesthe-
spective of providing high-quality anes-
uring improved postoperative outcomes
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and QoR. Although it has been reported that the perioperative
administration of dexmedetomidine improves QoR after major
abdominal and spinal surgeries,20,21 the outcomes for patients
who undergo thoracic surgery including VATS remain poorly
investigated.
The aims of this study were to evaluate the effects of
intraoperative dexmedetomidine administration on QoR by
using the QoR-40 and postoperative pulmonary function
in patients who undergo VATS. The hypothesis was that
intraoperative dexmedetomidine administration results in an
improved QoR after VATS.
METHODS
Study Population
This study received approval from the Institutional Review
Board of Severance Hospital (Ref. 4–2015–0284) on August 5,
2015 and was registered at clinicalTrials.gov (NCT02537249)
on August 24, 2015. All participants provided written informed
consent before participation. The inclusion criteria were as
follows: an American Society of Anesthesiologists physical
status of II or III, age >20 years, and the presence of non-
small cell lung cancer requiring VATS. Patients with a history of
arrhythmia, severe bradycardia (heart rate <45 beats/min),
severe functional liver or kidney disease, and psychiatric/central
nervous system disturbances that could preclude completion of
the QoR-40 were excluded.
Study Protocol
Enrolled patients were randomly allocated to Control
group or Dex group using a randomized sequence generated
by a computer, and randomization process was centralized.
Allocations were concealed in sealed envelopes, which were
sent to the anesthesia nurses who prepared dexmedetomidine or
saline solutions with comparable volume. The participating
anesthesiologist who infused the drug was blinded to random-
ization. Therefore, the surgeons, anesthesia and recovery
nurses, and patients were all blinded to randomization.
Patients were premedicated with glycopyrrolate 0.2mg.
On arrival to the operating room, the patient’s blood pressure,
oxygen saturation, electrocardiograms, and bispectral index
(BIS; A-200 monitor, Aspect Medical System Inc, Newton,
MA) were monitored. Anesthesia was induced with propofol
1.5 to 2.0mg/kg and remifentanil 1.0mg/kg. Following the loss
of consciousness, rocuronium 0.8mg/kg was administered to
facilitate tracheal intubation. Anesthetic maintenance was
achieved with desflurane at 1 minimum alveolar concentration
and remifentanil infused at 0.05 to 0.15mg /kg/min before skin
closure. After a loading dose of fentanyl 1.0mg/kg was intra-
venously injected, fentanyl at a dose 0.4mg/kg/h and ramose-
tron 0.6mg were infused through a patient-controlled analgesia
(PCA) system (Accufuser Plus; Woo Young Medical, Seoul,
Korea; flow rate 1mL/h, bolus volume 1mL, lock out time
15minutes) was started from 30minutes before the end of
surgery. After residual block was reversed, desflurane was
discontinued and the inspired oxygen flow was increased to
5L/min. Patients were extubated after BIS > 70 and a train-of-
four ratio of >0.9 were verified.
Intervention
Lee et alIn the Dex group, dexmedetomidine (Precedex; Hospira,
Lake Forest, IL) 200mg mixed with normal saline to achieve a
total volume of 50mL was administered. Dexmedetomidine
2 | www.md-journal.com1.0mg/kg was administrated for 20 minutes in Dex group. A
comparable volume of saline was administered in the Control
group. The dexmedetomidine or saline was administered for
20minutes before the termination of surgery.
Outcome Measures
The multidimensional QoR-40 questionnaire was used as a
measure for postoperative QoR, with the global score ranging
from 40 to 200. In total, the questionnaire contains 40 questions
pertaining to 5 domains: emotional state, physical comfort,
psychological support, physical independence, and pain.19
The patients completed this questionnaire before, at postopera-
tive day (POD) 1 and 2, respectively; the scoring system was
explained before the surgery, and an accurate understanding of
all questions was confirmed. After surgery, the questionnaires
were performed by an investigator blinded to randomization.
Postoperative pulmonary function was assessed using an auto-
mated flow-sensing spirometer (SPM-7; Bionet, Seoul, Korea)
for forced expiratory volume in 1 second (FEV1) measurement
on POD 1 and 2. The patients were assessed for signs of
emergence agitation for 2minutes after extubation using the
Riker sedation-agitation scale22: 1¼ unarousable—unrespon-
sive to noxious stimuli, cannot follow commands; 2¼ very
sedated—easily arouses to physical stimuli and/or may have
spontaneous movements, cannot follow commands; 3¼
sedated—difficult to arouse but arouses by verbal or physical
stimuli, follows commands; 4¼ calm and cooperative—calm
and easily arouses, follows commands; 5¼ agitated—shows
mild physical and/or emotional agitation or anxiety, calms with
verbal commands; 6¼ very agitated—show strong agitation/
anxiety, unable to calm with verbal commands and may require
restraints; 7¼ dangerous agitation—shows severe agitation/
anxiety, trying to remove endotracheal tube and/or catheters,
may attack staff. Severe agitation was defined as Riker sedation-
agitation scale 7. The times from cessation of desflurane to eye
opening as well as extubation were verified during emergence.
Also, we assessed the incidence of coughing during emergence
in both groups. Numeric rating scale (NRS: 0–10, 0¼ no pain;
5¼moderate pain; 10¼worst possible pain) at rest and cough-
ing were recorded at 10 and 30minutes after arrival to the
postanesthetic care unit (PACU). In PACU, arterial gas analysis
was performed at room air, and the partial pressure of arterial
oxygen (PaO2) and carbon dioxide (PaCO2) were assessed.
Patients were discharged from PACU when the modified
Aldrete score 23 was9 and the time of discharge was recorded.
The frequencies of postoperative opioid and rescue antiemetic
consumption on POD 1 and 2 were recorded. Perioperative data
were collected by an investigator not involved in treatment.
Postoperative pulmonary complications including atelectasis
and pneumonia, time to chest tube removal, incidence of
prolonged air leakage, and length of hospital stay were verified
for all patients.
Statistical Analysis
The primary outcome was the global QoR-40 score on
POD 1. The sample size was estimated on the basis of the
premise that a difference in the global QoR-40 score of 10 points
(standard deviation [SD], 14) between the Dex and Control
groups was clinically significant because 10 points difference
represents 15% improvement in the quality of recovery.24 We
Medicine  Volume 95, Number 7, February 2016found that 42 patients were required to achieve 90% power with
a significance level of (alpha) 0.05. Assuming a dropout rate of
20%, we enrolled 50 patients per group. The data were tested for
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
normality using the Kolmogorov–Smirnov test. Inter-group
comparisons were performed using an unpaired t test,
Mann–Whitney U test for continuous variables and Fisher
exact test for categorical variables. Values are expressed as
means SD for continuous variables and numbers (percen-
tages) for categorical variables. Parameters showing a non-
normal distribution are expressed as medians and interquartile
Medicine  Volume 95, Number 7, February 2016ranges (IQR). All statistical analyses were performed using
SPSS 20.0 (SPSS Inc, Chicago, IL) and P< 0.05 was con-
sidered statistically significant.
RESULTS
A total of 113 patients scheduled to undergo VATS were
assessed for eligibility between August 2015 and October 2015.
Two patients were excluded, and 111 patients were randomized
after obtaining informed consent (Figure 1). Eleven patients
were withdrawn from the study and 50 patients were randomly
assigned to each group. As shown in Table 1, demographic and
clinical characteristics showed no significant differences
between the groups.
FIGURE 1. CONSORT flow diagram.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.As shown in Table 2, baseline QoR-40 global and dimen-
sional scores were not different between the groups. The global
scores on POD 1 and 2 were significantly higher in the Dex
group compared with the Control group. On POD 1 and 2,
scores for the emotional state, physical comfort, and pain were
higher in the Dex group compared with the Control group
(Figure 2).
Perioperative data are presented in Table 3. The score of
emergence agitation was lower in the Dex group compared with
the Control group. The number of patients showing severe
emergence agitation was greater in the Control group than
Dex group. The incidence of coughing at extubation was
significantly lower in Dex group compared with the Control
group. The times from cessation of desflurane to eye opening as
well as extubation were delayed in the Dex group compared
with the Control group. PaO2 measured in PACU was higher in
the Dex group compared with the Control group. Although the
respiratory rate was lower in the Dex group compared with the
Dexmedetomidine on Quality of Recovery After VATSControl group, PaCO2 was not different between the groups.
Both NRS at rest and coughing, and opioid consumption in
PACUwere significantly lower in the Dex group compared with
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and atrial fibrillation were not significantly different between
TABLE 1. Baseline Demographic and Clinical Characteristics
Dex (n¼ 50) Control (n¼ 50) P
Age, y 62.0 10.5 62.0 11.5 0.715
Sex (male/female) 26 (52)/24 (48) 23 (46)/27 (54) 0.548
Height, cm 162.8 9.5 162.4 7.9 0.780
Weight, kg 62.0 0.8 65.0 0.8 0.612
Body mass index, kg/m2 23.6 0.4 23.6 0.4 0.783
ASA classification, n (%) 0.220
II 37 (74) 42 (84)
III 13 (26) 8 (16)
Comorbidity, n (%)
Hypertension 19 (83) 18 (69) 0.277
Diabetes 9 (39) 12 (46) 0.620
Smoking, n (%) 0.940
Ex-smoker/current smoker 6 (12)/15 (30) 5 (10)/16 (32)
Non-smoker 29 (58) 29 (58)
Smoking index, pack/year 30.2 0.4 34.7 0.4 0.411
PFT
FEV1, L 2.6 0.7 2.7 0.6 0.773
FEV1, % predicted 96.2 18.0 96.3 15.3 0.960
FVC, L 2.9 0.8 3.1 0.8 0.132
FVC, % predicted 95.2 15.2 94.5 13.8 0.799
FEV1/FVC (%) 77.5 7.4 77.3 8.1 0.977
DLco (%) 104.8 0.2 108.4 0.2 0.427
Histological type, n (%) 0.729
Squamous cell carcinoma 28 (56) 31 (62)
Adenocarcinoma 19 (38) 15 (30)
Others 3 (6) 4 (8)
Stage, n (%) 0.685
IA 31 (62) 36 (72)
IB 10 (20) 8 (16)
II A 7 (14) 4 (8)
II B 2 (4) 2 (4)
Side of operation, n (%) 0.420
Right 26 (52) 30 (60)
Left 24 (48) 20 (40)
Type of surgery, n (%) 0.819
Lobectomy 32 (64) 29 (58)
Segmentectomy 9 (18) 11 (22)
Wedge resection 9 (18) 10 (20)
Surgeon 1/2/3, n (%) 23 (46)/4 (8)/23 (46) 25 (50)/9 (18)/16 (22) 0.311
Data are presented as number (%) or meanSD or median (IQR). ASA¼American Society of Anesthesiologists, DLco¼ diffusion lung capacity,
city
Lee et al Medicine  Volume 95, Number 7, February 2016the Control group. The postoperative nausea and vomiting were
more frequent in the Control group; thus, incidence of admini-
strated anti-emetics was significantly higher in the Control
group compared with the Dex group. There were no differences
in the incidence of hypotension or bradycardia between the 2
groups. The discharge time from PACU was shorter in the Dex
group compared with the Control group. NRS at rest and cough
at ward were significantly lowered in the Dex group compared
with the Control group. FEV1 was significantly greater in the
Dex group compared with the Control group on POD 1 and 2.
Intravenous analgesia after surgery was required significantly
earlier in the Control group compared with the Dex group.
FEV1¼ forced expiratory volume in 1 second, FVC¼ forced vital capa
surgery.Moreover, the incidence of >3 requests for intravenous opioids
on POD 1 and 2 was significantly lower in the Dex group
compared with the Control group. Rescue anti-emetics were
4 | www.md-journal.comadministrated more frequently in the Control group compared
with the Dex group on POD 1 and 2.
As shown in Table 4, the incidence of postoperative
complications such as atelectasis, pneumonia, chylothorax,
, PFT¼ pulmonary function test, VATS¼ video-assisted thoracoscopicthe groups. The length of hospital stay was significantly shorter
in the Dex group compared with the Control group.
DISCUSSION
This study demonstrated that the quality of recovery was
significantly enhanced with intraoperative dexmedetomidine
administration in patients undergoing VATS. Postoperative
pulmonary function and oxygenation were also improved in
the Dex group, without increase in pulmonary complications.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.






Emotional state 39.6 3.2 39.9 3.5 0.667
Physical comfort 53.5 3.6 53.4 4.3 0.920
Psychological support 31.7 2.3 31.3 2.2 0.299
Physical independence 22.7 2.6 22.7 2.0 0.597
Pain 33.0 1.8 32.8 1.7 0.369
Global score 184.6 8.3 182.8 9.1 0.303
POD 1
Emotional state 37.1 5.6 33.6 4.3 <0.001
Physical comfort 46.9 7.0 43.0 7.7 0.009
Psychological support 31.0 3.2 30.0 3.1 0.051
Physical independence 21.8 3.9 20.9 4.0 0.183
Pain 28.4 3.7 26.1 4.5 0.006
Global score 162.3 17.8 153.3 18.7 0.016
POD 2
Emotional state 37.9 6.2 35.0 5.5 0.008
Physical comfort 49.3 8.1 45.8 7.3 0.019
Psychological support 32.0 3.1 31.0 3.2 0.095
Physical independence 21.6 3.9 21.3 3.7 0.517
Pain 31.0 3.6 28.9 4.7 0.008
Global score 174.3 16.0 166.8 16.7 0.028
FIGURE 2. Changes in QoR-40 global and dimensional scores
betweenDex andControl groups. Variables presented asmean stan-
Medicine  Volume 95, Number 7, February 2016 Dexmedetomidine on Quality of Recovery After VATSFinally, pain scores, emergence agitation, postoperative nausea
and vomiting, and opioid consumption were decreased with
dexmedetomidine administration. Although dexmedetomidine
administration prolonged the time to return of consciousness
from general anesthesia, discharge time from PACU and length
of hospital stay were significantly reduced.
The validity and reliability of the QoR-40 is clinically
significant for patient-related psychometric assessment in ver-
ifying patient satisfaction.18,19, In our study, emotional state,
physical comfort, and pain among 5 dimensions of QoR-40
were improved by dexmedetomidine administration. The
physical comfort dimension consists of postoperative nausea/
vomiting, shivering, restlessness, and fatigue. Nausea and
vomiting are triggered by opioid use and high catecholamine
levels,25 and dexmedetomidine is known to have beneficial
effects on early postoperative nausea and vomiting, particularly
in high-risk patients.12 Although there were no differences in
surgery-related complications between the groups, the length of
hospital stay was significantly reduced in the Dex group. These
results provide further evidence for dexmedetomidine attenuat-
ing the general condition, as it can improve the quality of
recovery in respect of the patients’ physical comfort and
emotional status. Therefore, dexmedetomidine acts as an
important contributor in raising patient satisfaction and reliev-
ing postoperative pain.
In this study, moderate pain after VATS was sustained
despite of the application of PCA. Several studies have
confirmed the analgesic and opioid-sparing effects of dexme-
detomidine after major surgery.10,17,20 Intraoperative dexme-
detomidine administration decreased immediate postoperative
pain and improved QoR-40 for the pain dimension from after
Data are presented as meanSD. POD¼ postoperative day.surgery until POD 2. Dexmedetomidine has a relatively short
elimination half-life of 2 to 2.5 hours.26 However, during that
time, dexmedetomidine acts as a sedative by its sympatholytic
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.standard deviation. POD¼postoperative day, Preop¼preoperative,
QoR-40¼quality of recovery 40 questionnaire. P<0.05 compared
with Control group.properties. Dexmedetomidine enhances the analgesic effects
of coadministered analgesics16; distinctively, a synergic anti-
nociceptic action occurs when coadministering a2-adrenergic
www.md-journal.com | 5
TABLE 3. Perioperative Data
Dex (n¼ 50) Control (n¼ 50) P
In operating room
Agitation profile
Emergence agitation score 3 (2–5) 5 (3–7) <0.001
Severe emergence agitation, n (%) 0 (0) 7 (14) 0.048
Coughing at extubation, n (%) 4 (8) 13 (26) 0.016
Recovery time, min
Time to eye opening 15.4 4.8 10.4 3.0 <0.001
Time to extubation 20 (19–21) 18 (17–19) <0.001
Duration of surgery, min 100 (69–200) 100 (80–158) 0.785
Duration of anesthesia, min 125 (75–250) 125 (100–210) 0.626
Fluid intake, mL 995.5 411.4 897.5 382.5 0.223
Blood loss, mL 47.0 23.9 35.2 29.1 0.303
Urine output, mL 108.1 75.1 117.6 62.5 0.732
In PACU
Respiratory variables at room air
Respiratory rate, breaths/min 17 (9–28) 21 (10–30) 0.023
PaO2, mmHg 86.0 (71.9–122.3) 80.7 (57.9–100.1) 0.027
PaCO2, mmHg 40.0 (28.0–45.1) 40.2 (35.0–51.7) 0.204
Pain
NRS at rest -10 min 4 (2–10) 7 (2–10) 0.001
NRS with cough-10 min 6 (0–10) 8 (2–10) <0.001
NRS at rest -30 min 6 (2–10) 6 (2–10) 0.007
NRS with cough -30 min 6 (0–10) 7 (2–10) 0.001
Opioid consumption
Rescue fentanyl, n (%) 29 (58) 41 (82) 0.008
Rescue fentanyl dose, mg 40 (0–100) 69 (0–100) 0.002
Number of rescue anti-emetics, n (%)
0/1/2 50 (100)/0 (0)/0 (0) 42 (85.7)/6 (12.2)/1 (2.0) 0.006
Bradycardia, n (%) 2 (4) 0 (0) 0.495
Hypotension, n (%) 2 (4) 0 (0) 0.495
Vasoactive drug administration, n (%)
Ephedrine 2 (4) 0 (0) 0.495
Atropine 2 (4) 0 (0) 0.495
Time to PACU discharge, min 50 (30–80) 59 (13–126) 0.045
At ward
Pain
NRS at rest-6 h 3 (0–6) 5 (2–7) 0.014
NRS at cough-6 h 5 (2–8) 6 (3–9) 0.021
FEV1, L
POD 1 2.1 0.4 1.9 0.5 0.034
POD 2 2.2 0.5 2.0 0.4 0.030
Opioid consumption
Time to first rescue analgesics, min 210 (0–820) 120 (0–360) 0.032
Intravenous analgesics on POD 1, n (%)
1 37 (74) 35 (70) 0.656
3 5 (10) 13 (26) 0.037
Intravenous analgesics on POD 2, n (%)
1 38 (76) 41 (82) 0.461
3 4 (8) 12 (24) 0.029
PONV, n (%)
Number of rescue anti-emetics
0/1/2 on POD 1 48 (96)/1 (2)/1 (2) 39 (78)/10 (20)/1 (2) 0.008
0/1/2 on POD 2 49 (98)/1 (2)/0 (0) 40 (80)/10 (20)/0 (0) 0.004
Data are presented as number (%), meanSD or median (IQR). FEV1¼ forced expiratory volume in 1 second, NRS¼ numeric rating scale,
PaCO2¼ partial pressure of arterial carbon dioxide tension, PACU¼ post-anesthetic care unit, PaO2¼ partial pressure of arterial oxygen tension,
POD¼ postoperative day, PONV¼ postoperative nausea and vomiting.
Lee et al Medicine  Volume 95, Number 7, February 2016
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Atelectasis 2 (4) 3 (6) > 0.99
Pneumonia 1 (2) 2 (4) > 0.99
Chylothorax 0 (0) 1 (2) > 0.99
Atrial fibrillation 1 (2) 1 (2) > 0.99
Time to chest tube removal, days 2 (1–8) 3 (1–7) 0.808
Prolonged air leakage
(>7 days), n (%)
4 (8) 3 (6) > 0.99
Length of hospital stay, days 6.7 (3–9) 8.4 (4–9) 0.045
Medicine  Volume 95, Number 7, February 2016agonists and m-receptor agonists.27 Yet, it is not fully clarified
whether the analgesic properties of dexmedetomidine have any
long-lasting effects. According to Ge et al,20 in addition to the
downstream mechanism of a2-adrenergic receptor, dexmede-
tomidine extends the analgesics time of other analgesics,
thereby indirectly having a long-lasting proanalgesic effect.
In accordance, our result reflected that dexmedetomidine could
have a synergistic effect with fentanyl, a m-receptor agonist.
Therefore, the improved postoperative pain score can be attribu-
table to both direct effects and indirect effects of dexmedeto-
midine with coadministration of fentanyl-based intravenous
patient-controlled analgesia. In this study, dexmedetomidine
induced smooth emergence after VATS. To our knowledge,
there were no previous studies focusing on emergence agitation
after thoracic surgery. Emergence agitation is multifactorial and
has been linked to severe pain from the surgical site and factors
that may cause physical irritation such as urinary catheteriza-
tion.28 In our study, the average NRS after VATS was 7 for the
Control group, and a causal relationship between severe pain
and emergence agitation can be considered. Consequently,
dexmedetomidine administration may be an effective way to
ameliorate emergence agitation for patient undergoing VATS.
In our result, intraoperative dexmedetomidine adminis-
tration improved arterial oxygenation in the PACU and pul-
monary function on POD 1 and 2. Postoperative pulmonary
function was known to relate with pain after thoracic
surgery.29,30 Incision pain prevents patients from sighing and
taking deep breaths and suppresses coughing to expectorate
sputum; this can cause ineffective ventilation. Therefore, the
pain-modulating effect of dexmedetomidine could have
improved postoperative oxygenation. Also, opioid-sparing
effect of dexmedetomidine could contribute to reduce the
opioid-induced respiratory depression. Although dexmedetomi-
dine administration delayed the emergence time from general
anesthesia by extending the time to eye opening and extubation;
it paradoxically shortened the discharge time from PACU by
attennuating pain, PONV, and respiratory function.
The length of hospital stay after VATS can be influenced
by several factors including age, performance status, and post-
operative pulmonary function.31 In addition to these socio-
environmental and clinical factors, it is important to consider
Data are presented as number (%) or median (IQR).psychological factors, which can also manipulate postoperative
length of hospital stay.32 In the present study, there were no
significant differences of social demographic factors or clinical
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.factors including comorbidity and acquired postoperative com-
plications between the 2 groups. Nevertheless, the Dex group
showed superior QoR scores and emotional scores, and overall
psychological statuses of the patients were improved. Amelior-
ating the psychological distress of patients reduced the length of
hospital stay, which in return can also yield larger hospital cost
savings. Although we were not able to confirm the long-term
effects of dexmedetomidine, Myles et al33 reported poor quality
of recovery can predict a poor quality of life after surgery. Thus,
dexmedetomidine administration during VATS can increase
QoR, promote quality of life, and lead to a higher satisfaction
rate for patients after surgery.
This study has several limitations. First, we enrolled
patients with lung cancer whose cardiopulmonary function is
relatively normal before surgery. Therefore, our results are not
applicable to patients with high marginal cardiopulmonary
function. Although dexmedetomidine administration has been
related to severe bradycardia, hypotension, and cardiac arrest,
such side-effects were not appeared in our study. Therefore,
additional studies are needed to investigate the effects of
dexmedetomidine on patients with compromised cardiopul-
monary function undergoing VATS. Second, previous stu-
dies20,21 investigated the use of dexmedetomidine on its
effects of adequate analgesia or postoperative recovery with
both loading doses and maintenance infusion of dexmedetomi-
dine. In this study, dexmedetomidine was administrated as
much as loading dose without maintenance dose. Our results
suggest that to improve QoR and postoperative pulmonary
function, a large dose of dexmedetomdine is not necessary to
achieve such beneficial postoperative outcomes. Further studies
are needed to specify the range of dexmedetomidine dosage
required to achieve such beneficial postoperative outcomes.
In conclusion, our results suggested that intraoperative
dexmedetomidine administration could improve the quality
of recovery and postoperative pulmonary function in patients
undergoing VATS. These findings were related with the
decrease in pain, postoperative nausea and vomiting, emergence
agitation, and opioid consumption by dexmedetomidine admin-
istration. Consequently, intraoperative dexmedetomidine
administration could improve postoperative outcomes and
reduced the hospital stay in patients undergoing VATS.
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